Can LDL cholesterol be too low? Possible risks of extremely low levels

Journal of Internal Medicine

Volumn 281, Issue 6, 2017, Pages 534-553

  Olsson, A G ^a   Angelin, B ^b   Assmann, G ^c   Binder, C J ^d   Bjorkhem I ^b   Cedazo Minguez, A ^e   Cohen, J ^f   von Eckardstein, A ^g   Farinaro, E ^h   Muller Wieland D ⁱ   Parhofer, K G ^j   Parini, P ^b   Rosenson, R S ^k   Starup Linde, J ^l   Tikkanen, M J ^m   Yvan Charvet, L ⁿ  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k MOUNT SINAI HOSPITAL   (United States)

^l AARHUS UNIVERSITY   (Denmark)

^m UNIVERSITY OF HELSINKI   (Finland)

ⁿ UNIVERSITÉ CÔTE D'AZUR   (France)

more..

Author keywords

abetalipoproteinaemia; adverse effects; hypocholesterolaemia; low density lipoprotein; safety

Indexed keywords

ALIROCUMAB; ANGIOPOIETIN; ANGIOPOIETIN LIKE 3; ATORVASTATIN; BILE ACID; BILE ACID SEQUESTRANT; BOCOCIZUMAB; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; MONOCLONAL ANTIBODY; NICOTINIC ACID; PLACEBO; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE 9 INHIBITOR; ROSUVASTATIN; SERINE PROTEINASE INHIBITOR; SEX HORMONE; STEROID HORMONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN;

ABETALIPOPROTEINEMIA; ARTICLE; BILE ACID SYNTHESIS; BLOOD BRAIN BARRIER; BONE METABOLISM; BRAIN FUNCTION; CELL FUNCTION; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COGNITION; DEPRESSION; DRUG SAFETY; GENE MUTATION; GENETIC DISORDER; HORMONE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOBETALIPOPROTEINEMIA; HYPOCHOLESTEROLEMIA; IMMUNE SYSTEM; INFECTION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MALIGNANT NEOPLASM; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; BLOOD; BONE; BRAIN; CARDIOVASCULAR DISEASES; GENETICS; IMMUNITY; METABOLISM; MUTATION; NEOPLASM; PHYSIOLOGY;

BONE AND BONES; BRAIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNE SYSTEM PHENOMENA; LIPOPROTEINS, LDL; MUTATION; NEOPLASMS; PROPROTEIN CONVERTASE 9; RISK FACTORS;

EID: 85019597621     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12614     Document Type: Article

References (106)

1. Goldstein Joseph L, Brown Michael S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161: 161–72.
2. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–9.
3. Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–99.
4. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Investig 2002; 109: 1125–31.
5. Kotzka J, Müller-Wieland D. Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Therapeutic Targets 2004; 8: 141–9.
6. Parini P, Johansson L, Bröijersén A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006; 36: 98–104.
7. Apro J, Parini P, Broijersén A, Angelin B, Rudling M. Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. J Lipid Res 2015; 56: 1633–9.
8. Rudling MJ, Reihnér E, Einarsson K, Ewerth S, Angelin B. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Natl Acad Sci USA 1990; 87: 3469–73.
9. Vitols S, Angelin B, Ericsson S et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA 1990; 87: 2598–602.
10. Illingworth D, Lees AM, Lees RS. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 1983; 32: 1045–52.
11. Illingworth D, Kenny T, Connor W, Orwoll ES. Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH. J Lab Clin Med 1982; 100: 115–26.
12. Illingworth D, Kenny T, Orwoll E. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982; 54: 27–33.
13. Chiang JYL. Bile acid metabolism and signaling. Comprehensive Physiol 2013; 3: 1191–212.
14. Deckelbaum RJ, Lees RS, Small DM, Hedberg SE, Grundy SM. Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia. N Engl J Med 1977; 296: 465–70.
15. Reihnér E, Rudling M, Ståhlberg D et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990; 323: 224–8.
16. Naoumova RP, O'Neill FH, Dunn S et al. Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur J Clin Invest 1999; 29: 404–12.
17. Hillebrant C, Nyberg B, Einarsson K, Eriksson M. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans. Gut 1997; 41: 700–4.
18. Sharp D, Blinderman L, Combs KA et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365: 65–9.
19. Welty FK. Hypobetalipoproteinemia and Abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161–8.
20. Abifadel M, Varret M, Rabès JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154–6.
21. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279: 50630–8.
22. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004; 101: 7100–5.
23. Benjannet S, Rhainds D, Essalmani R et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the LDLR and LDL-cholesterol. J Biol Chem 2004; 279: 48865–75.
24. Cohen JC, Boerwinkle E, Mosley TH Jr et al. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. N Engl J Med 2006; 354: 1264–72.
25. Linsel-Nitschke P, Gotz A, Erdmann J et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease–a Mendelian Randomisation study. PLoS ONE 2008; 3: e2986.
26. Willer CJ, Sanna S, Jackson AU et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40: 161–9.
27. Cohen JC, Boerwinkle E, Mosley TH et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 34–42.
28. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55: 2833–42.
29. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63: 2889–934.
30. Members ATF, Piepoli MF, Hoes AW et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–96.
31. Zhao Z, Tuakli-Wosornu Y, Lagace TA et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514–23.
32. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193: 445–8.
33. Cariou B, Ouguerram K, Zair Y et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009; 29: 2191–7.
34. Musunuru K, Pirruccello JP, Do R et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363: 2220–7.
35. Virani SS, Woodard LD, Landrum CR et al. Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J 2011; 161: 1140–6.
36. Hegele RA, Gidding SS, Ginsberg HN et al. ATVB council statement: non-statin LDL-lowering therapy and cardiovascular risk reduction. Arterioscler Thromb Vasc Biol 2015; 35: 2269–80.
37. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–57.
38. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406–15.
39. -1 with rosuvastatin: the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2011; 57: 1666–75.
40. -1) With Rosuvastatin 20 mg Daily (from JUPITER). Am J Cardiol 2014; 114: 1682–9.
41. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015; 65: 2638–51.
42. Ballantyne CM, Neutel J, Cropp A et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin Type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115: 1212–21.
43. Robinson JG, Rosenson RS, Farnier M et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. J Am Coll Cardiol 2017; 69: 471–82.
44. Robinson JG, Rosenson RS, Farnier M et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol 2017; 69: 471–82.
45. Moriarty PM, Jacobson TA, Bruckert E et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014; 8: 554–61.
46. Lipinski MJ, Benedetto U, Escarcega RO et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2015; 37: 536–45.
47. Khan AR, Bavishi C, Riaz H et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin Type 9 inhibitors. Circ Cardiovasc Qual Outcomes 2017; 10: 1–11.
48. Kastelein JJP, Nissen SE, Rader DJ et al. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. Eur Heart J 2016; 37: 1360–9.
49. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; https://doi.org/10.1056/NEJMoa1615664.
50. Blom DJ, Djedjos CS, Monsalvo ML et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-Week, Phase 3, double-blind, randomized. Placebo-controlled DESCARTES study. Circ Res 2015; 117: 731–41.
51. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clinical Invest 1995; 95: 1124–32.
52. Nicholls S, Puri R, Anderson T et al. Effect of evolocumab on progression of coronary disease in statin-treated patients the GLAGOV randomized clinical trial. JAMA 2016; 316: 2373–84.
53. White J, Swerdlow D, Preiss D et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol 2016; 1: 692–9.
54. Schmidt AF, Swerdlow DI, Holmes MV et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2017; 5: 97–105.
55. Ference BA, Robinson JG, Brook RD et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016; 375: 2144–53.
56. Besseling J, Kastelein JP, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313: 1029–36.
57. Preiss D, Seshasai S, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556–64.
58. Colhoun HM, Ginsberg HN, Robinson JG et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J 2016; 37: 2981–9.
59. Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med 2015; 3: 2050312115605518.
60. Betteridge DJ, Carmena R. The diabetogenic action of statins [mdash] mechanisms and clinical implications. Nat Rev Endocrinol 2016; 12: 99–110.
61. Swerdlow DI, Preiss D, Kuchenbaecker KB et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351–61.
62. Rütti S, Ehses JA, Sibler RA et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic β-cells. Endocrinology 2009; 150: 4521–30.
63. Kruit JK, Kremer PHC, Dai L et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010; 53: 1110–9.
64. Knebel B, Haas J, Hartwig S et al. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE 2012; 7: e31812.
65. Kotzka J, Knebel B, Haas J et al. Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity. PLoS ONE 2012; 7: e32609.
66. Parini P, Gustafsson U, Davis MA et al. Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Arterioscler Thromb Vasc Biol 2008; 28: 1200–6.
67. Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med 2011; 269: 333–9.
68. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532–61.
69. Langsted A, Freiberg JJ, Tybjærg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011; 270: 65–75.
70. Lv Y-B, Yin Z-X, Chei C-L et al. Low-density lipoprotein cholesterol was inversely associated with 3-year all-cause mortality among Chinese oldest old: data from the Chinese longitudinal healthy longevity survey. Atherosclerosis 2015; 239: 137–42.
71. Casiglia E, Mazza A, Tikhonoff V et al. Total cholesterol and mortality in the elderly. J Intern Med 2003; 254: 353–62.
72. Reddy VS, Bui QT, Jacobs JR, Begelman SM, Miller DP, French WJ. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (The Lipid Paradox). Am J Cardiol 2015; 115: 557–62.
73. Chien Y-F, Chen C-Y, Hsu C-L, Chen KY, Yu CJ. Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission. J Crit Care 2015; 30: 506–10.
74. Yamano S, Shimizu K, Ogura H et al. Low total cholesterol and high total bilirubin are associated with prognosis in patients with prolonged sepsis. J Crit Care 2016; 31: 36–40.
75. Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. Can Med Assoc J 2012; 184: E367–72.
76. Walley K. Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis. Curr Opin Crit Care 2016; 22: 464.
77. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015; 15: 104–16.
78. Ni H, Liu H, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PLoS ONE 2015; 10: e0142669.
79. Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011; 103: 508–19.
80. Folsom AR, Peacock JM, Boerwinkle E. Sequence variation in proprotein convertase subtilisin/kexin Type 9 serine protease gene, low LDL cholesterol, and cancer incidence. Cancer Epidemiol Biomark Prev 2007; 16: 2455–8.
81. Goldstein MR, Mascitelli L, Pezzetta F. Primary prevention of cardiovascular disease with statins: cautionary notes. QJM: Int J Med 2009; 102: 817–20.
82. Shepherd J, Blauw GJ, Murphy M et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet 2002; 360: 1623–30.
83. Hague WE, Simes J, Kirby A et al. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: sixteen years of follow-up of the LIPID study. Circulation 2016; 133: 1851–60.
84. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792–802.
85. Assimes TL, Hólm H, Kathiresan S et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 2010; 56: 1552–63.
86. Starup-Linde J, Gregersen S, Vestergaard P. Associations with fracture in patients with diabetes: a nested case–control study. BMJ Open 2016; 6: e009686.
87. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24: 806–15.
88. Kivipelto M, Hikala E, Hänninen T et al. Midlife vascular factors and late-life mild cognitive impairment: a population based study. Neurology 2001; 56: 1683–9.
89. Sparks DL, Scheff SW, Hunsaker Iii JC, Liu H, Landers T, Gross DR. Induction of alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126: 88–94.
90. Heverin M, Maioli S, Pham T et al. 27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res 2015; 278: 356–9.
91. Babiker A, Dzeletovic S, Wiklund B et al. Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 2005; 65: 365–76.
92. Ismail M-A-M, Mateos L, Maioli S et al. 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. J Exp Med 2017; 214: 699–717.
93. Mateos L, Ismail M-A-M, Gil-Bea F-J et al. Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism. J Biol Chem 2011; 286: 25574–85.
94. Shafaati M, Marutle A, Pettersson H et al. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. J Lipid Res 2011; 52: 1004–10.
95. McGuinness B, Passmore P. Can statins prevent or help treat Alzheimer's disease? J Alzheimer's Disease 2010; 20: 925–33.
96. Thelen KM, Rentsch KM, Gutteck U et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2006; 316: 1146–52.
97. Kotti TJ, Ramirez DMO, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 2006; 103: 3869–74.
98. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy: J Human Pharmacol Drug Therapy 2003; 23: 871–80.
99. Persons J, Robinson J, Coryell W, Payne ME, Fiedorowicz JG. Longitudinal study of low serum LDL cholesterol and depressive symptom onset in postmenopause. J Clin Psychiatry 2016; 77: 212–20.
100. De Berardis D, Marini S, Piersanti M et al. The relationships between cholesterol and suicide: an update. ISRN Psychiatry 2012; 2012: 387901.
101. Almeida-Montes LG, Valles-Sanchez V, Moreno-Aguilar J et al. Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts. J Psychiatry Neurosci 2000; 25: 371–7.
102. Tsai S, Kuo C, Chen C et al. Risk factors for completed suicide in bipolar disorder. J Clin Psychiatry 2002; 63: 469–76.
103. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322: 11–5.
104. Asellus P, Nordström P, Jokinen J. Cholesterol and CSF 5-HIAA in attempted suicide. J Affect Disord 2010; 125: 388–92.
105. Eriksson M, Eklundh T, Sjöberg S, Angelin B, Nordin C. Cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers. Biol Psychiat 1996; 40: 302–4.
106. Angelin B, Parini P. Lipoprotein metabolism. In: Wass JAH, Stewart PM, eds. Oxford Textbook of Endocrinology and Diabetes, 2nd ed. Oxford: Oxford University Press, 2011; 1659–1667.